MedTrace Logo

ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

NCT00396240 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1294

Last updated 2009-03-26

No results posted yet for this study

Summary

24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance. If the subject does not reach the EAS LDL-C treatment goal at week 12, rosuvastatin will be titrated from 10mg to 20mg.

Conditions

  • Primary Hypercholesterolaemia

Interventions

DRUG

Rosuvastatin

PROCEDURE

Initiatives to improve compliance

Sponsors & Collaborators

Principal Investigators

  • Madeleine Billeter, MD · AstraZeneca

  • W. Riesen, MD · Cantonal Hospital of St. Gallen

  • R. Darioli, MD · CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00396240 on ClinicalTrials.gov